Abbott's FreeStyle Libre Glucose Monitoring System Now Reimbursed across Japan
5 September 2017 - - Abbott Park, Illinois-based global healthcare products company Abbott (NYSE: ABT) has been granted reimbursement for the FreeStyle Libre glucose monitoring system by the Ministry of Health Labour and Welfare in Japan, effective September 1, 2017, the company said.
The system will be widely available to the more than 1 million Japanese people ages six and above with diabetes, both Type 1 and Type 2, on insulin therapy. Japan has one of the highest rates of diabetes with an overall population of 9.5 million people living with the condition.
Japan now joins a group of 16 countries that have partially or fully covered Libre, including large markets such as France and Germany. In the US, the FreeStyle Libre system is currently under review by the US Food and Drug Administration.
Two published clinical trials and real-world evidence from more than 50,000 users show that people who use FreeStyle Libre system test their glucose levels an average of at least 15 times per day.
The studies also show that people who scan more frequently spend less time in hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar) while having improved average glucose levels, demonstrating improved glucose control overall.
Abbott's FreeStyle Libre system is designed to change how people with diabetes measure their glucose levels and ultimately help them achieve better health outcomes. The system reads glucose levels through a sensor that can be worn on the back of the upper arm for up to 14 days, and does not require finger stick calibration.
Abbott Laboratories manufactures and sells health care products worldwide, including nutrition, diagnostics, medical devices, and branded generic pharmaceuticals. The company employs roughly 94,000 people, and serves more than 150 countries.